Head-to-Head Study Showed Prasugrel Statistically Superior To Clopidogrel In Reducing Recurrent Cardiovascular Events A new, pre-specified analysis of the landmark Phase III head-to-head TRITON-TIMI 38 study showed patients who took prasugrel for acute coronary syndromes (ACS) managed with an artery-opening procedure known as percutaneous coronary intervention (PCI) and had survived their first cardiov
Source: www.medicalnewstoday.comNamibia Holds Workshop, Conducts Assessment To Examine Male Circumcision For HIV Prevention In order for Namibia to increase access to male circumcision in an effort to curb the spread of HIV in the country, resources need to be mobilized and
health facilities nationwide better prepared, Minister of
Health and Social Services Richard Kamwi said recently, the New Era/AllAfrica.com reports. According to the New Era/AllAfrica.
Source: www.medicalnewstoday.comCancer Therapy: A Role For MAPK Inhibitors Combined With MTORC1 Inhibitors Nearly a decade ago, while it was being tested as an immunosuppressive agent to prevent organ rejection in transplant patients, the drug rapamycin was also discovered to have anti-tumor properties. Since then, several rapamycin analogs known as mTOR (mammalian target of rapamycin) inhibitors have been tested in clinical trials for the treatment of various types of cancer.
Source: www.medicalnewstoday.comBiodiesel Byproduct Converted Into Omega-3 Fatty Acids By Virginia Tech Researcher The typical American diet often lacks omega-3 fatty acids despite clinical research that shows their potential human
health benefits. Zhiyou Wen, assistant professor of biological systems engineering in Virginia Tech's College of Agriculture and Life Sciences, found a way to grow these compounds using a byproduct of the emerging biodiesel industry.
Source: www.medicalnewstoday.comFDA Approves Vidaza Label Expansion The Aplastic Anemia & MDS International Foundation (AA&MDSIF) is pleased to inform patients that the U.S. Food & Drug Administration (FDA) has expanded the label for VIDAZA (azacitidine) to include data from the AZA-001 trial, which found that Vidaza is the only agent that extends survival in MDS (myelodysplastic syndromes) patients.
Source: www.medicalnewstoday.comUNAIDS In Bangladesh, Standard Chartered Bank Sign Agreement To Form Business Coalition On HIV/AIDS Representatives from Standard Chartered Bank and UNAIDS in Bangladesh recently signed an agreement to create a business coalition on HIV/AIDS in the country, the New Nation reports. The coalition aims to encourage businesses and other institutions in Bangladesh to provide resources and skills, as well as to create an environment that promotes an effective response to the disease.
Source: www.medicalnewstoday.com
# posted by Network @ 4:00 PM
